United Therapeutics Target Price

See United Therapeutics's analyst price targets ($650) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$591.17

Average Target Price

$652.50

10.4% upside

14 analysts in the last 4 months

High: $850 | Low: $321

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-11-09	H.C. WainwrightMatthew Caufield	$660	11.6% upside
2026-11-05	Wells FargoBen Burnett	$703	18.9% upside
2026-11-04	Raymond JamesTiago Fauth	$720	21.8% upside
2026-10-28	J.P. Morgan	$695	17.6% upside
2026-10-26	Cantor FitzgeraldOlivia Brayer Saunders	$850	43.8% upside
2026-10-22	RBC Capital	$697	17.9% upside
2026-10-20	Raymond James	$717	21.3% upside
2026-10-19	UBS	$725	22.6% upside
2026-10-15	Goldman Sachs	$368	37.8% downside
2026-10-14	JefferiesRoger Song	$728	23.1% upside
2026-10-08	RBC Capital	$708	19.8% upside
2026-10-01	BTIG	$728	23.1% upside
2026-09-24	Goldman SachsAndrea Newkirk	$321	45.7% downside
2026-08-06	Morgan StanleyTerence Flynn	$515	12.9% downside
2026-05-07	Wells Fargo	$735	24.3% upside
2026-05-07	Morgan StanleyTerence Flynn	$516	12.7% downside
2026-05-07	Wells Fargo	$738	24.8% upside
2026-04-10	Morgan StanleyTerence Flynn	$519	12.2% downside
2026-04-10	Raymond James	$700	18.4% upside
2026-03-12	Cantor FitzgeraldOlivia Brayer	$625	5.7% upside
2026-02-26	H.C. WainwrightAndrew Fein	$600	1.5% upside
2026-01-06	UBS	$645	9.1% upside
2025-11-19	JefferiesEun Yang	$575	2.7% downside
2025-10-30	H.C. WainwrightAndrew Fein	$525	11.2% downside
2025-10-30	RBC CapitalLisa Walter	$587	0.7% downside
2025-10-29	Morgan StanleyTerrance Flynn	$447	24.4% downside
2025-10-10	Morgan StanleyTerence Flynn	$435	26.4% downside
2025-09-29	UBS	$580	1.9% downside
2025-09-26	RBC Capital	$569	3.8% downside
2025-09-10	Cantor FitzgeraldOlivia Brayer	$525	11.2% downside
2025-09-05	H.C. WainwrightAndrew Fein	$500	15.4% downside
2025-09-02	JefferiesRoger Song	$564	4.6% downside
2025-07-31	H.C. WainwrightAndrew Fein	$400	32.3% downside
2025-04-25	Wells FargoTiago Fauth	$314	46.9% downside
2024-10-31	Argus ResearchJasper Hellweg	$400	32.3% downside
2024-10-31	H.C. WainwrightAndrew Fein	$425	28.1% downside
2024-09-23	JefferiesEun Yang	$432	26.9% downside
2024-08-28	OppenheimerHartaj Singh	$575	2.7% downside
2024-07-08	UBSAshwani Verma	$370	37.4% downside
2024-06-12	Wells FargoTiago Fauth	$350	40.8% downside
2024-05-02	OppenheimerHartaj Singh	$400	32.3% downside
2024-02-12	Goldman SachsChris Shibutani	$215	63.6% downside
2023-01-11	Argus Research	$300	49.3% downside
2022-12-06	Morgan Stanley	$330	44.2% downside
2022-12-06	UBS	$320	45.9% downside
2022-12-05	Goldman Sachs	$230	61.1% downside
2022-05-24	J.P. Morgan	$238	59.7% downside
2022-05-24	Jefferies	$245	58.6% downside
2022-05-24	Credit Suisse	$247	58.2% downside
2022-05-24	H.C. Wainwright	$255	56.9% downside

United Therapeutics (UTHR) FAQ

United Therapeutics posts a target price of $650. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $650 for UTHR means covering analysts, on average, see the stock 10.4% upside of $591.17 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for UTHR's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; United Therapeutics's other metric pages and overview cover the third.

Judging United Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $650 here, then scan peer and history charts to see if the gap is persistent.